Publication Information: KTH, Center for the Advancement of Integrated Medical and Engineering Sciences, AIMES
KTH, Mikro- och nanosystemteknik
KTH, Nanobioteknologi
KTH, Science for Life Laboratory, SciLifeLab
Karolinska Inst, Ctr Adv Integrated Med & Engn Sci AIMES, S-17177 Stockholm, Sweden.;KTH Royal Inst Technol, S-17177 Stockholm, Sweden.;Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.;Univ Basque Country, Sch Pharm, Lab Pharmaceut, NanoBioCel Res Grp,UPV EHU, Vitoria 01006, Spain.;Inst Hlth Carlos III, Biomed Res Networking Ctr Bioengn Biomat & Nanome, Madrid 28029, Spain.;NanoBioCel Res Grp, Bioaraba, Vitoria 01006, Spain.
Karolinska Inst, Ctr Adv Integrated Med & Engn Sci AIMES, S-17177 Stockholm, Sweden.; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.
Univ Basque Country, Sch Pharm, Lab Pharmaceut, NanoBioCel Res Grp,UPV EHU, Vitoria 01006, Spain.;Inst Hlth Carlos III, Biomed Res Networking Ctr Bioengn Biomat & Nanome, Madrid 28029, Spain.; NanoBioCel Res Grp, Bioaraba, Vitoria 01006, Spain.
Univ Basque Country, Sch Pharm, Lab Pharmaceut, NanoBioCel Res Grp,UPV EHU, Vitoria 01006, Spain.;Inst Hlth Carlos III, Biomed Res Networking Ctr Bioengn Biomat & Nanome, Madrid 28029, Spain.;NanoBioCel Res Grp, Bioaraba, Vitoria 01006, Spain.
Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.
Springer Nature
Abstract: Background Neurodegenerative diseases (NDs) are an accelerating global health problem. Nevertheless, the stronghold of the brain- the blood–brain barrier (BBB) prevents drug penetrance and dwindles effective treatments. Therefore, it is crucial to identify Trojan horse-like drug carriers that can effectively cross the blood–brain barrier and reach the brain tissue. We have previously developed polyunsaturated fatty acids (PUFA)-based nanostructured lipid carriers (NLC), namely DHAH-NLC. These carriers are modulated with BBB-permeating compounds such as chitosan (CS) and trans-activating transcriptional activator (TAT) from HIV-1 that can entrap neurotrophic factors (NTF) serving as nanocarriers for NDs treatment. Moreover, microglia are suggested as a key causative factor of the undergoing neuroinflammation of NDs. In this work, we used in vitro models to investigate whether DHAH-NLCs can enter the brain via the BBB and investigate the therapeutic effect of NTF-containing DHAH-NLC and DHAH-NLC itself on lipopolysaccharide-challenged microglia. Methods We employed human induced pluripotent stem cell-derived brain microvascular endothelial cells (BMECs) to capitalize on the in vivo-like TEER of this BBB model and quantitatively assessed the permeability of DHAH-NLCs. We also used the HMC3 microglia cell line to assess the therapeutic effect of NTF-containing DHAH-NLC upon LPS challenge. Results TAT-functionalized DHAH-NLCs successfully crossed the in vitro BBB model, which exhibited high transendothelial electrical resistance (TEER) values (≈3000 Ω*cm2). Specifically, the TAT-functionalized DHAH-NLCs showed a permeability of up to 0.4% of the dose. Furthermore, using human microglia (HMC3), we demonstrate that DHAH-NLCs successfully counteracted the inflammatory response in our cultures after LPS challenge. Moreover, the encapsulation of glial cell-derived neurotrophic factor (GNDF)-containing DHAH-NLCs (DHAH-NLC-GNDF) activated the Nrf2/HO-1 pathway, suggesting the triggering of the endogenous anti-oxidative ...
No Comments.